Business

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results

Management to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

articleAtyr Pharma, Inc.November 3, 20215/company/atyr-pharma-inc/news/atyr-pharma-to-webcast-conference-call-reporting-third-quarter-2021-financial-results
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results

About this update from Atyr Pharma, Inc.

[{"type":"text","content":"Management to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST\nSAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third quarter 2021 financial results and provide a corporate update after the market close on Wednesday, November 10, 2021. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Wednesday, November 10th @ 5:00 pm EST / 2:00 pm PSTDomestic: 844-358-9116International: 209-905-5951Conference ID: 9134928Webcast: http://investors.atyrpharma.com/events-and-webcasts About aTyr aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. Contact:Ashlee DunstonDirector, Investor Relations and Corporate [email protected] \nSource: aTyr Pharma, Inc.","length":3477,"tagName":"div"}]

More updates from Atyr Pharma, Inc.